ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    J

    Dr Joshua Reuss, MD

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    BEAMION safety

    Joshua Reuss, MD
    Lung Cancer
    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)

    BEAMION secondary efficacy

    Joshua Reuss, MD
    Lung Cancer
    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)

    Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)

    BEAMION efficacy

    Joshua Reuss, MD
    Lung Cancer